Boosting Bacterial Metabolism to Combat Antibiotic Resistance

The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>As Published</td>
<td><a href="http://dx.doi.org/10.1016/j.cmet.2015.01.012">http://dx.doi.org/10.1016/j.cmet.2015.01.012</a></td>
</tr>
<tr>
<td>Publisher</td>
<td>Elsevier</td>
</tr>
<tr>
<td>Version</td>
<td>Author’s final manuscript</td>
</tr>
<tr>
<td>Accessed</td>
<td>Fri May 25 21:44:51 EDT 2018</td>
</tr>
<tr>
<td>Citable Link</td>
<td><a href="http://hdl.handle.net/1721.1/108625">http://hdl.handle.net/1721.1/108625</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>Creative Commons Attribution-NonCommercial-NoDerivs License</td>
</tr>
<tr>
<td>Detailed Terms</td>
<td><a href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</a></td>
</tr>
</tbody>
</table>
Boosting bacterial metabolism to combat antibiotic resistance

Prerna Bhargava and James J Collins*

Institute for Medical Engineering & Science, Department of Biological Engineering, and Synthetic Biology Center, Massachusetts Institute of Technology; Broad Institute of MIT and Harvard; Wyss Institute for Biologically Inspired Engineering, Harvard University

*Correspondence: jimjc@mit.edu

ABSTRACT: The metabolic state of a bacterial cell influences its susceptibility to antibiotics. In this issue, Peng et al. show that resistant bacteria can be sensitized to antibiotic treatment through the addition of exogenous metabolites that stimulate central metabolic pathways and increase drug uptake.

The role of metabolism in the bacterial response to antibiotics has recently garnered interest because of a rapid rise in antibiotic resistance, a clear link between metabolic function and cell viability, and the lack of novel targets for hard-to-treat infections. A large body of evidence suggests that bacterial metabolism is closely tied to antibiotic susceptibility. Bacteria with reduced metabolism are resistant or tolerant to many classes of antibiotics, while increased drug sensitivity is linked to enhanced metabolism (Allison et al., 2012; Bryan and Van Den Elzen, 1977; Kohanski et al., 2007; Martínez and Rojo, 2011). Little is known, however, about the metabolic profiles of genetically resistant bacterial populations. Peng et al. address this topic in this issue of Cell Metabolism (8, 2015).

To investigate the metabolic state of resistant bacteria, Peng et al. (8, 2015) evolved Edwardsiella tarda (E. tarda), an opportunistic pathogen in humans and fish, against the aminoglycoside antibiotic, kanamycin. Resistant E. tarda strains had altered metabolic profiles, with defects observed in central metabolic pathways (Fig 1a). Resistant strains exhibited the greatest deficiencies in glucose and alanine abundances. These findings are consistent with previous work in resistant strains of Stenotrophomonas maltophilia and Pseudomonas aeruginosa (Alonso, 2004; Stickland et al., 2010), which were found to exhibit defects in central metabolism, specifically glucose and amino acid metabolism.

It is generally accepted that the acquisition of genetic resistance determinants results in a metabolic cost for bacteria, such that susceptible bacteria will efficiently outcompete resistant bacteria in the absence of selection pressures (Lázár et al., 2014). This notion is rooted in the fact that constantly replicating large plasmids containing resistance genes, or producing enzymes that inactivate antibiotics, would lead to a large metabolic burden. Several mechanisms of known resistance have been documented, ranging from drug-degrading enzymes to efflux pumps. These mechanisms afford different levels of protection for a population of bacteria, and the metabolic impact of each of these resistance mechanisms varies.
depending on their fitness cost (Martínez and Rojo, 2011). The bacterial strains that
were subjected to metabolomic analysis in the Peng study were evolved in vitro
under the selection pressure of kanamycin, though more experimentation is needed
to identify the underlying resistance mechanisms that arose in these strains.

Given the metabolic deficiencies observed in resistant strains of E. tarda,
Peng and co-authors hypothesized that addition of the deficient metabolites could
increase the susceptibility of the resistant bacteria to antibiotic treatment.
Challenging kanamycin-resistant E. tarda with alanine and/or glucose plus
kanamycin indeed sensitized the bacteria to the antibiotic. Further, it was found that
cells treated with alanine and glucose had higher intracellular levels of kanamycin.
This enhancement in drug uptake was shown to be a result of increased proton
motive force, due to greater flux through the tricarboxylic acid (TCA) cycle (Fig 1b).
This work indicates that metabolite-enabled increases in central metabolic flux can
enhance drug uptake and bacterial killing in resistant bacteria.

Alanine and glucose supplementation was also able to increase
aminoglycoside-induced killing in lab-evolved beta lactam-resistant, quinolone-
resistant, and tetracycline-resistant strains of E. tarda, respectively. Further, the
lethal effects of aminoglycoside treatment in several other human pathogens,
including Klebsiella pneumonia, methicillin-resistant Staphylococcus aureus, and
Pseudomonas aeruginosa, were enhanced with the addition of these metabolites.
Biofilms and persisters of clinical pathogenic isolates of E. tarda were also
successfully targeted with the same approach. This is consistent with previous work
by Allison et al. which showed that addition of exogenous metabolites (e.g., glucose,
mannitol, fructose) could stimulate central metabolic pathways and enable
aminoglycosides to eradicate E. coli and S. aureus persisters and biofilms (Allison et
al., 2012). Together, these works show that metabolic stimuli can boost the
toxic effects of aminoglycosides across many species in different
physiological states.

The addition of exogenous metabolites to restore metabolic deficiencies
offers an attractive approach to treat drug-resistant pathogens in combination with
antibiotics that would otherwise be ineffective (Murima et al., 2014). It is important
to note, however, that the metabolic burden on a resistant pathogen is highly
dependent on the bacterial microenvironment and the metabolic adaptations
required for colonizing such a habitat. The work by Peng et al. raises many
questions about the role of environmental metabolic signals in the efficacy of
antibiotics. Bacteria generate a large number of metabolites, many of which have
unknown or incompletely understood biological functions, and metabolites
produced by one class of bacteria can influence the antibiotic susceptibility of
neighboring bacteria within a niche (Vega et al., 2013). Further studies are needed
to understand more completely the role of metabolites in in vivo infection
microenvironments.
Along these lines, little is known about the role of host metabolites in the regulation of antibiotic efficacy. Interestingly, severe and recurrent infections tend to manifest more frequently within hosts that are immunocompromised, suggesting that the host environment, including the metabolome, could significantly influence the rate of infection, the efficacy of antibiotics, and the generation of resistance. Expanding on these studies will provide insights into how bacterial and host metabolism can influence antibiotic efficacy, potentially leading to personalized infection control strategies based on a patient’s metabolic state.

Investigating the relationships between bacterial metabolism and antibiotic sensitivity can help to uncover novel strategies for treating infections. The report by Peng et al. highlights the significance of the metabolic environment in antibiotic resistance and treatment strategies. It will be important to build upon this work and examine how the metabolic state varies with different resistance mechanisms and across different environmental conditions. Further studies may allow us to develop generalized metabolic therapeutics as co-treatments for already prescribed antibiotics, thereby expanding a rapidly shrinking arsenal of effective therapies against resistant and persistent infections.

**Figure 1: Exogenous addition of metabolites enhances antibiotic uptake leading to cell death.** a) Antibiotic-resistant cells have lower metabolite abundances leading to reduced PMF, inhibited drug uptake and no cell death. b) Exogenous addition of alanine and/or glucose can enhance drug uptake and restore cell sensitivity.

**ACKNOWLEDGEMENTS:** We thank Caleb Bashor for his help with figure design.
REFERENCES


